Lv Y, Jun Y, Tang Z, et al. Int J Nanomedicine. 2020;15:10075–10084.
The authors have advised due to an error at the time of figure assembly, Figure 5C on page 10082 is incorrect. The correct Figure 5 is shown below.
Figure 5.
Therapeutic effects of Mac/EYLNs-Dox on 4T1 tumors. Subcutaneous implant 4T1 tumor mice were treated with PBS, Dox, EYLNs-Dox and Mac/EYLNs-Dox, (A) tumor growth was recorded every 3 days. (B) Mice were sacrificed 30 days after treatment, tumors were removed and photographed. (C) 4T1 lung metastasis model was established and treated with PBS, Dox, EYLNs-Dox and Mac/EYLNs-Dox every 5 days for 5 times, the metastatic tumors were detected by in vivo imaging and the tumor signals were quantified (D). After 5 times treatment, mice were sacrificed and the lungs were removed, stained with and photographed (E), the pathology of lungs was analyzed by HE staining (F). *p<0.05, **p<0.01. Scale bar: 500μm.
The authors apologize for this error and advise it does not affect the results of the paper.